搜索筛选:
搜索耗时2.7071秒,为你在为你在102,285,761篇论文里面共找到 8 篇相符的论文内容
类      型:
[期刊论文] 作者:Hai-Bo Qiu,Zhao-Lei Zeng,Zhi-Q, 来源:世界胃肠病学杂志:英文版(电子版) 年份:2011
瞄准:评估肝炎 B 的效果 colorectal 癌症的肝转移上的病毒(HBV ) 感染。方法:1298 个 colorectal 癌症病人的一个总数在这研究从 2001 年 1 月被招募到 2005 年 3 月。连接酶...
[会议论文] 作者:Dong-dong Yang,Zhan-Hong Chen,De-Shen Wang,Yu Hong-En,Jia-Huan Lu,Rui-Hua Xu,Zhao-Lei Zeng, 来源:2019中国肿瘤学大会 年份:2019
[期刊论文] 作者:Hai-Bo Qiu,Li-Yi Zhang,Zhao-Lei Zeng,Zhi-Qiang Wang,Hui-Yan Luo,Rajiv Prasad Keshari,Zhi-Wei Zhou,Rui-Hua, 来源:世界胃肠病学杂志(英文版) 年份:2011
[会议论文] 作者:Hongen Yu,Huiyan Luo,Feng Wang,Fang Yu,Zhao-lei Zeng,Yun Wang,Yun-xin Lu,Ying Jin,Huai-Qiang Ju,Rui-hua, 来源:2019中国肿瘤学大会 年份:2019
Objective Gastric cancer(GC)is one of the most common malignancies worldwide.Due to the low rate of early detection,most GC patients were diagnosed as advance stages and had poor response to chemother...
[期刊论文] 作者:Xiao-Li Wei,De-Shen Wang,Shao-Yan Xi,Wen-Jing Wu,Dong-Liang Chen,Zhao-Lei Zeng,Rui-Yu Wang,Ya-Xin Huang, 来源:World Journal of Gastroenterology 年份:2014
AIM:To explore the association between AT-rich interactive domain 1A(ARID1A)protein loss by immunohistochemistry and both clinicopathologic characteristics and...
[会议论文] 作者:Zongwei Cai,Dan Xie,Peng Huang,Xin-Yuan Guan,Li Fu,Jian-biao Li,Yanru Qin,Ting-ting Zeng,Jie Zhou,Zhao-lei Zeng, 来源:中国病理生理学会第十四届肿瘤专业委员会、第十五届免疫专业委员会联合学术会议 年份:2014
Background & Aims: Solid tumors often become hypoxic,leading to activation of hypoxia-response genes.We investigated the effects of overexpression of the hypoxia response genes eIF5A2 (eukaryotic init...
[会议论文] 作者:Feng Wang,De-shen Wang,Zhao-lei Zeng,Rui-hua Xu,Zhe-zhen Li,Yun-xin Lu,Zhi-qiang Wang,Long Bai,Dong-liang, 来源:第四届广州国际肿瘤学会议 年份:2015
  The present observational cohort study was designed to elucidate the efficacy and safety profile of bevacizumab or cetuximab in the first-line treatment of...
[会议论文] 作者:Ren,Dong-sheng Zhang,Qi Zhao,De-shen Wang,Dong-liang Chen,Yun-xin Lu,Huai-qiang Ju,Hui-yan Luo,Zhao-lei Zeng, 来源:第四届广州国际肿瘤学会议 年份:2015
The present observational cohort study was designed to elucidate the efficacy and safety profile of bevacizumab or cetuximab in the first-line treatment of metastatic colorectal cancer(mCRC)in Chinese...
相关搜索: